---
title: Impact of the 1970 Indian Patent Act
videoId: WkylI-78U6c
---

From: [[asianometry]] <br/> 

The **Indian Patent Act of 1970** fundamentally reshaped India's pharmaceutical landscape, driving its growth into a global leader in generic drugs and ensuring widespread access to affordable medicines within the country <a class="yt-timestamp" data-t="00:03:12">[00:03:12]</a>.

## Background: A Nation in Need
Prior to the Act, India's drug industry was heavily dependent on foreign entities. In 1947, following India's independence, millions lacked access to basic drugs <a class="yt-timestamp" data-t="00:01:25">[00:01:25]</a>. Eight of the top ten pharmaceutical firms were Western multinationals, primarily from the UK, France, and Germany, holding a dominant 90% market share <a class="yt-timestamp" data-t="00:01:33">[00:01:33]</a>. Domestic Indian companies focused mainly on marketing and distributing foreign drugs, rather than developing their own <a class="yt-timestamp" data-t="00:01:42">[00:01:42]</a>. Consequently, almost all drugs were imported <a class="yt-timestamp" data-t="00:01:50">[00:01:50]</a>, and domestic drug prices were among the highest globally, with 99% of drugs locked up in patents, making them accessible only to the wealthy <a class="yt-timestamp" data-t="00:01:52">[00:02:02]</a>.

The Indian government attempted to address this over-reliance on imports through [[government_intervention_in_technology_industries | government intervention]], establishing public sector pharmaceutical firms like Hindustan Antibiotics Limited (HAL) in 1954 and Indian Drugs and Pharmaceuticals Limited (IDPL) in cooperation with the Soviets a few years later <a class="yt-timestamp" data-t="00:02:14">[00:02:29]</a>.

A pivotal moment occurred in the 1960s when the British pharmaceutical company ICI Pharmaceuticals developed Propranolol, a high blood pressure medication. Its cost made it prohibitive for use in India <a class="yt-timestamp" data-t="00:02:44">[00:02:47]</a>. An Indian company, Sipla, began manufacturing a generic version for the Indian market <a class="yt-timestamp" data-t="00:02:47">[00:02:51]</a>. When ICI complained, Sipla's R&D head, Yusuf Hamied, justified his actions to then-Prime Minister Indira Gandhi, who, recognizing the argument's merit, urged parliament to modify drug patent laws <a class="yt-timestamp" data-t="00:02:54">[00:03:10]</a>. This led directly to the passing of the 1970 Patent Act <a class="yt-timestamp" data-t="00:03:12">[00:03:16]</a>.

## Key Provisions and Goals of the 1970 Act
The 1970 Patent Act had two primary objectives <a class="yt-timestamp" data-t="00:03:21">[00:03:22]</a>:
1.  **Low-cost access to drugs**: To make medicines affordable for the general population <a class="yt-timestamp" data-t="00:03:24">[00:03:26]</a>.
2.  **Indigenous industry development**: To foster a domestic Indian pharmaceutical industry and encourage import substitution <a class="yt-timestamp" data-t="00:03:26">[00:03:33]</a>.

Crucially, the Act replaced India's previous patent laws (last updated in 1872, rooted in British IP law, and protecting products) with a new system that protected the *process* of manufacturing a drug rather than the *product* itself <a class="yt-timestamp" data-t="00:03:36">[00:03:58]</a>. This meant that if an Indian company could find a different process to make an existing patented drug, they could do so legally <a class="yt-timestamp" data-t="00:04:01">[00:04:05]</a>.

Additionally, the Act set shorter time limits for these process patentsâ€”approximately five to seven years after filing, compared to the 15 years under the old law <a class="yt-timestamp" data-t="00:04:07">[00:04:14]</a>. It also granted the Indian patent office the authority to compel patent holders to license patents at a reasonable rate if they were not being used in a socially beneficial manner <a class="yt-timestamp" data-t="00:04:17">[00:04:28]</a>.

## Immediate Impact: Rise of Reverse Engineering
This new system opened up vast opportunities for the [[history_of_indias_pharmaceutical_industry | Indian pharmaceutical industry]] <a class="yt-timestamp" data-t="00:04:31">[00:04:35]</a>. It became possible to reverse-engineer virtually any popular imported drug for the Indian market <a class="yt-timestamp" data-t="00:04:38">[00:04:42]</a>. Managers and scientists from public sector laboratories capitalized on this legal shift <a class="yt-timestamp" data-t="00:07:32">[00:07:40]</a>. As a result, the number of pharmaceutical firms in India more than doubled between 1970 and 1980 <a class="yt-timestamp" data-t="00:07:40">[00:07:44]</a>.

These early domestic companies primarily focused on reverse engineering, studying the sequential steps of drug production and making slight modifications to create a "new process" <a class="yt-timestamp" data-t="00:07:48">[00:08:32]</a>. While this approach might seem "cheap and derivative," it allowed Indian companies to build significant competency in pharmaceuticals <a class="yt-timestamp" data-t="00:08:44">[00:08:49]</a>. By the end of the 1980s, Indian firms could manufacture almost any new molecule without needing the original innovator's recipes <a class="yt-timestamp" data-t="00:08:52">[00:08:59]</a>.

The time gap between the introduction of original innovations and Indian generics steadily decreased, demonstrating the improving reverse engineering capabilities of domestic firms <a class="yt-timestamp" data-t="00:09:02">[00:09:13]</a>:
*   Ibuprofen, introduced globally in 1967, saw its first Indian generic in 1973 (a 6-year gap) <a class="yt-timestamp" data-t="00:09:15">[00:09:23]</a>.
*   Ciprofloxacin, introduced by Bayer in 1986, had an Indian generic version in just three years <a class="yt-timestamp" data-t="00:09:26">[00:09:50]</a>.

By 2006, Indian companies supplied 95% of the country's drugs, signifying the success of import substitution <a class="yt-timestamp" data-t="00:09:56">[00:10:02]</a>.

## Drawbacks and Evolution: Post-TRIPS Era
Despite its successes, the 1970 Patent Act also had drawbacks <a class="yt-timestamp" data-t="00:10:05">[00:10:08]</a>. The industry it fostered was high in volume but low in value <a class="yt-timestamp" data-t="00:10:11">[00:10:17]</a>. With low barriers to entry and minimal capital requirements, the number of pharmaceutical companies exploded to around 16,000 by 1990 <a class="yt-timestamp" data-t="00:10:17">[00:10:25]</a>. This led to extreme fragmentation, vast overcapacity, and razor-thin margins, forcing companies to focus on producing as many molecules as possible as cheaply as possible <a class="yt-timestamp" data-t="00:10:27">[00:10:52]</a>. Without adequate resources, incentives, or intellectual property protections for new discoveries, the domestic industry invested little in R&D and produced few new drugs <a class="yt-timestamp" data-t="00:10:53">[00:11:02]</a>.

This situation began to change with India's signing of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) in 1992 <a class="yt-timestamp" data-t="00:11:21">[00:11:26]</a>. TRIPS required India to amend its patent policies to align with international standards, including recognizing product patents and granting exclusive marketing rights for new products <a class="yt-timestamp" data-t="00:11:37">[00:11:51]</a>. Although controversial, with some arguing against stringent IP rights based on past negative impacts <a class="yt-timestamp" data-t="00:11:53">[00:12:10]</a>, India was given until 2005 to prepare its industry for these changes <a class="yt-timestamp" data-t="00:12:17">[00:12:22]</a>.

From 1992 to 2005, the industry underwent a "monumental shift," moving away from its decades-long successful model towards a more profitable, innovation-driven one <a class="yt-timestamp" data-t="00:13:30">[00:13:41]</a>.
*   Some firms like Ranbaxy, DRL, and Wockhardt invested in R&D to climb the value chain and enter drug discovery <a class="yt-timestamp" data-t="00:12:52">[00:12:57]</a>.
*   Annual R&D spend accelerated from 4.9% before 1992 to 6.6% after <a class="yt-timestamp" data-t="00:13:21">[00:13:25]</a>.
*   Pharmaceutical drug patents by Indian institutions increased significantly: from 9 (1990-1994) to 48 (1995-1998) and further to 227 (1999-2002) <a class="yt-timestamp" data-t="00:13:37">[00:13:50]</a>.
*   The government encouraged R&D through schemes, creating coordinating bodies and a pharmaceutical R&D support fund <a class="yt-timestamp" data-t="00:13:55">[00:14:11]</a>.

While drug discovery remained expensive and challenging for most smaller firms <a class="yt-timestamp" data-t="00:14:22">[00:14:44]</a>, many companies diversified by investing in drug-adjacent fields like drug delivery <a class="yt-timestamp" data-t="00:14:52">[00:14:59]</a>, strengthening other parts of the value chain like marketing and production <a class="yt-timestamp" data-t="00:15:01">[00:15:05]</a>, forming strategic collaborations with multinationals (e.g., Zydus Cadila, Biocon) <a class="yt-timestamp" data-t="00:15:07">[00:15:43]</a>, or scaling up through mergers and acquisitions <a class="yt-timestamp" data-t="00:15:43">[00:15:52]</a>.

## Legacy and Current Position
The 1970 Patent Act, and its subsequent re-application of IP rights following TRIPS, was crucial in India's pharmaceutical success <a class="yt-timestamp" data-t="00:19:03">[00:19:09]</a>. It allowed India to transform from an import-dependent nation to the world's largest provider of generic drugs <a class="yt-timestamp" data-t="00:00:22">[00:00:24]</a>. The US, for instance, relies on India for 40% of its generics <a class="yt-timestamp" data-t="00:00:24">[00:00:26]</a>. In 2020, India exported $16 billion more in pharmaceuticals than it imported, meeting strict global standards <a class="yt-timestamp" data-t="00:00:30">[00:00:40]</a>.

The Act exemplified "market-driven reform sparked by a change in the environment," allowing India to make changes based on what was right for its circumstances, rather than adhering to rigid ideology <a class="yt-timestamp" data-t="00:19:11">[00:19:24]</a>.

Today, India's generics industry is highly competitive internationally, bolstered by lower costs and expertise gained from its challenging domestic market <a class="yt-timestamp" data-t="00:16:15">[00:16:25]</a>. This export success has been further aided by favorable generic drug regulatory environments, such as the US Hatch-Waxman Act of 1984, which facilitated FDA approval of generic drugs <a class="yt-timestamp" data-t="00:16:27">[00:16:37]</a>. Indian companies like Dr. Reddy's Laboratories and Marksans Pharma dramatically increased their export ratios following the 2005 TRIPS implementation <a class="yt-timestamp" data-t="00:16:39">[00:17:11]</a>. The industry's sales to North America, Africa, and Asia have grown nearly eightfold since then <a class="yt-timestamp" data-t="00:17:13">[00:17:18]</a>.

A current challenge is India's dependence on China for 70% of its active pharmaceutical ingredients (APIs) <a class="yt-timestamp" data-t="00:17:21">[00:17:43]</a>. India lost its domestic API market to cheaper Chinese products in the 1990s <a class="yt-timestamp" data-t="00:17:54">[00:18:03]</a>. This weakness became pronounced during China's 2020 lockdowns, leading to stock shortages and export restrictions on certain ingredients <a class="yt-timestamp" data-t="00:18:11">[00:18:25]</a>. Geopolitical tensions further underscore the need for India to work with the government on new import substitution policies for APIs <a class="yt-timestamp" data-t="00:18:25">[00:18:41]</a>.

Ironically, as India moved away from process-based patents, other countries began to adopt similar models, recognizing how India's 1970 Act helped lower drug costs and break the hold of multinationals <a class="yt-timestamp" data-t="00:18:41">[00:19:00]</a>. Despite remaining concerns, India's pharmaceutical industry is poised to play a significant role in addressing global health issues in the future <a class="yt-timestamp" data-t="00:19:31">[00:19:42]</a>.